Shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX – Get Free Report) have been given an average rating of “Moderate Buy” by the twenty research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation, twelve have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $120.44.
A number of research firms recently issued reports on BNTX. HC Wainwright dropped their target price on shares of BioNTech from $130.00 to $110.00 and set a “buy” rating on the stock in a research report on Monday, November 9th. Citigroup reduced their price target on shares of BioNTech from $130.00 to $125.00 and set a “buy” rating for the company in a report on Wednesday, August 5th. Morgan Stanley decreased their price target on shares of BioNTech from $114.00 to $106.00 and set an “overweight” rating for the company in a research note on Wednesday, November 4th. Wall Street Zen upgraded shares of BioNTech from a “sell” rating to a “hold” rating in a report on Saturday, November 7th. Finally, Berenberg Bank set a $140.00 price objective on shares of BioNTech in a report on Wednesday, September 16th.
Check Out Our Latest Report on BNTX
BioNTech Stock Performance
Insider Activity at BioNTech
In related news, CEO Ugur Sahin sold 36,209 shares of the company’s stock in a transaction that occurred on Friday, October 9th. The stock was sold at an average price of $95.37, for a total transaction of $3,453,252.33. Following the transaction, the chief executive officer directly owned 36,209 shares of the company’s stock, valued at approximately $3,453,252.33. This represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 807,209 shares of company stock valued at $79,246,837. Company insiders own 19.20% of the company’s stock.
Institutional Investors Weigh In On BioNTech
Hedge funds have recently added to or reduced their stakes in the company. Dodge & Cox increased its holdings in shares of BioNTech by 0.3% during the third quarter. Dodge & Cox now owns 3,687,791 shares of the company’s stock valued at $362,510,000 after acquiring an additional 10,200 shares in the last quarter. Flossbach Von Storch SE bought a new stake in shares of BioNTech during the second quarter worth about $207,142,000. First Trust Advisors LP raised its holdings in shares of BioNTech by 25.9% in the 3rd quarter. First Trust Advisors LP now owns 996,312 shares of the company’s stock worth $97,937,000 after acquiring an additional 204,843 shares during the last quarter. Bank of America Corp DE raised its stake in shares of BioNTech by 22.6% in the first quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock worth $80,261,000 after purchasing an additional 166,432 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of BioNTech by 79.7% in the third quarter. Assenagon Asset Management S.A. now owns 760,675 shares of the company’s stock valued at $74,774,000 after purchasing an additional 337,412 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.
BioNTech Company Profile
BioNTech SE is a biotechnology company based in Mainz, Germany. Founded in 2008, it develops medicines and vaccines, with a focus on immunotherapies for cancer and infectious diseases. The company’s research uses technologies including messenger RNA (mRNA), antibodies, and cell-based therapies. Its best-known product is Comirnaty, an mRNA vaccine against COVID-19 developed and commercialized in partnership with Pfizer. BioNTech also has a broad oncology research and development portfolio. BioNTech works with partners to develop and distribute products internationally.
Recommended Stories
- Five stocks we like better than BioNTech
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.
